• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by 89bio Inc.

    10/17/24 10:46:57 AM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ETNB alert in real time by email
    SC 13G/A 1 89bio_Inc.htm SCHEDULE 13G Amendment No. 15

     

      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     

    89BIO INC

    (Name of Issuer)
     

    COMMON STOCK

    (Title of Class of Securities)
     

    282559103

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 5 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    282559103 13G Page 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    STATE STREET CORPORATION

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 04-2456637

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    MA

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    3,040,036

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    3,251,687

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,251,687.00

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.1%

    12

    TYPE OF REPORTING PERSON

    HC

             

     

     

     

    282559103 13G Page 3 of 5 Pages

     

    Item 1(a). NAME OF ISSUER
       
      89BIO INC

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
       
      535 MISSION STREET 14TH FLOOR SAN FRANCISCO CA 94105 UNITED STATES

     

    Item 2(a). NAME OF PERSON FILING
       
     

    STATE STREET CORPORATION

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES

     

    Item 2(c). CITIZENSHIP
       
      MA

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      COMMON STOCK

     

    Item 2(e). CUSIP NUMBER
       
      282559103

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§240.13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

    STATE STREET CORPORATION (a) Broker or dealer registered under Section 15 of the Act;
      (b) Bank as defined in Section 3(a)(6) of the Act;
      (c) Insurance company as defined in Section 3(a)(19) of the Act;
      (d) Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f)

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

      (g) X

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h)

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i)

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K).
      If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     

    282559103 13G Page 4 of 5 Pages

     

    Item 4. OWNERSHIP
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount beneficially owned: 3,251,687.00  
      (b) Percent of class: 3.1%  
      (c) Number of shares as to which the person has:    
             
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote 3,040,036
        (iii) Sole power to dispose or to direct the disposition of 0
        (iv) Shared power to dispose or to direct the disposition of 3,251,687
             
      Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following
      ý
      Instruction: Dissolution of a group requires a response to this item.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      NOT APPLICABLE

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      SSGA FUNDS MANAGEMENT, INC. (IA) STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA) STATE STREET GLOBAL ADVISORS LIMITED (IA) STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA) STATE STREET GLOBAL ADVISORS, LTD. (IA)

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      NOT APPLICABLE

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      NOT APPLICABLE

     

    Item 10. CERTIFICATION

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11
       

     

     

     

    282559103 13G Page 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: October 14, 2024

     

       
         
         
        ELIZABETH SCHAEFER, SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
         
         

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    Get the next $ETNB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ETNB

    DatePrice TargetRatingAnalyst
    3/14/2025$11.00Neutral
    Goldman
    3/13/2025$25.00Buy
    Citigroup
    2/4/2025Outperform
    Wolfe Research
    4/22/2024$30.00Buy
    BofA Securities
    1/12/2024$24.00 → $15.00Outperform → Sector Perform
    RBC Capital Mkts
    10/10/2023Outperform → Perform
    Oppenheimer
    8/28/2023$36.00Buy
    UBS
    6/13/2023$49.00Outperform
    Evercore ISI
    More analyst ratings

    $ETNB
    SEC Filings

    See more
    • SEC Form 8-K filed by 89bio Inc.

      8-K - 89bio, Inc. (0001785173) (Filer)

      5/30/25 4:18:52 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by 89bio Inc.

      SCHEDULE 13G/A - 89bio, Inc. (0001785173) (Subject)

      5/15/25 8:29:03 AM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by 89bio Inc.

      SCHEDULE 13G/A - 89bio, Inc. (0001785173) (Subject)

      5/14/25 12:00:28 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETNB
    Leadership Updates

    Live Leadership Updates

    See more
    • 89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

      SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer, effective today. Dr. Perney brings an extensive track record of expertise and leadership in Regulatory, Product Development and Quality in the industry to the Company. "We are delighted to welcome Dr. Teresa Perney to our executive leadership team at this critical juncture for 89bio," said Rohan Palekar, CEO of 89bio. "As we advance pegozafermin through

      9/16/24 4:05:00 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 89bio Appoints Francis Sarena as Chief Operating Officer

      SAN FRANCISCO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Francis Sarena as Chief Operating Officer, effective August 5, 2024. "We are excited to welcome Francis to our executive team at this pivotal growth phase for 89bio," said Rohan Palekar, CEO of 89bio. "As we advance our Phase 3 clinical program for pegozafermin and prepare for scale up, Francis' extensive strategic, operational, business development and leadership expertise will be immensely valuable. His prov

      8/7/24 8:00:00 AM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 89bio Appoints Charles McWherter, Ph.D., to its Board of Directors

      SAN FRANCISCO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Dr. Charles McWherter to its Board of Directors, effective July 30, 2024. Dr. McWherter most recently served as Chief Scientific Officer and President of Research and Development of CymaBay Therapeutics until it was acquired by Gilead Sciences in March 2024. "We are thrilled to welcome Charles, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, CEO of 89bio. "His expertise in drug dev

      8/5/24 8:00:00 AM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETNB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. bought $49,999,994 worth of shares (5,714,285 units at $8.75) (SEC Form 4)

      4 - 89bio, Inc. (0001785173) (Issuer)

      2/3/25 5:38:09 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mcwherter Charles bought $99,850 worth of shares (15,000 units at $6.66), increasing direct ownership by 150% to 25,000 units (SEC Form 4)

      4 - 89bio, Inc. (0001785173) (Issuer)

      1/23/25 7:38:31 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Palekar Rohan bought $39,450 worth of shares (5,000 units at $7.89), increasing direct ownership by 1% to 471,236 units (SEC Form 4)

      4 - 89bio, Inc. (0001785173) (Issuer)

      12/10/24 6:02:26 AM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETNB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on 89bio with a new price target

      Goldman initiated coverage of 89bio with a rating of Neutral and set a new price target of $11.00

      3/14/25 7:36:30 AM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on 89bio with a new price target

      Citigroup initiated coverage of 89bio with a rating of Buy and set a new price target of $25.00

      3/13/25 7:35:31 AM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on 89bio

      Wolfe Research initiated coverage of 89bio with a rating of Outperform

      2/4/25 7:02:09 AM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETNB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by 89bio Inc.

      SC 13D/A - 89bio, Inc. (0001785173) (Subject)

      11/18/24 8:19:11 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by 89bio Inc.

      SC 13G/A - 89bio, Inc. (0001785173) (Subject)

      11/14/24 4:30:44 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by 89bio Inc.

      SC 13G/A - 89bio, Inc. (0001785173) (Subject)

      11/14/24 12:47:48 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETNB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Le-Nguyen Quoc sold $91,208 worth of shares (15,329 units at $5.95), decreasing direct ownership by 4% to 328,323 units (SEC Form 4)

      4 - 89bio, Inc. (0001785173) (Issuer)

      4/17/25 4:05:16 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Le-Nguyen Quoc was granted 14,750 shares and covered exercise/tax liability with 1,050 shares, decreasing direct ownership by 0.30% to 343,652 units (SEC Form 4)

      4 - 89bio, Inc. (0001785173) (Issuer)

      2/19/25 4:01:10 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Martins Ryan covered exercise/tax liability with 780 shares, decreasing direct ownership by 0.29% to 269,674 units (SEC Form 4)

      4 - 89bio, Inc. (0001785173) (Issuer)

      2/19/25 4:01:07 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETNB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 183,885 shares of the Company's common stock to seven new employees (the "Inducement Grants") on May 6, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the "Plan"). The Inducement Grants were gran

      5/9/25 4:05:00 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 89bio to Participate in Upcoming Investor Conferences

      SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in the following investor conferences during the month of May: BofA Securities 2025 Health Care ConferenceFormat: Fireside ChatDate: Wednesday, May 14, 2025Time: 1:40 PM ET 2025 RBC Capital Markets Global Healthcare ConferenceFormat: Fireside ChatDate: Tuesday, May 20, 2025Time: 9:30 AM ET The webcast of the fireside chats will be accessible in the invest

      5/6/25 4:05:00 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 89bio Reports First Quarter 2025 Financial Results and Corporate Updates

      – Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) has been fully enrolled and topline data are expected in 1Q 2026 – – Cash, cash equivalents, and marketable securities totaled $638.8 million as of March 31, 2025; completed follow-on equity offering in 1Q 2025 with gross proceeds of $287.5 million – SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage

      5/1/25 4:05:00 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETNB
    Financials

    Live finance-specific insights

    See more
    • 89bio's Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks

      - 44mg Q2W dose had a placebo-adjusted effect size of 20% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 24% on NASH resolution without worsening of fibrosis (p=0.0005) - - 30mg QW dose had a placebo-adjusted effect size of 19% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 21% on NASH resolution without worsening of fibrosis (p=0.0009) - - 44mg Q2W and 30mg QW doses had at least one-stage fibrosis improvement without worsening of NASH at 3.5 times placebo rate and NASH resolution without worsening of fibrosis at 12 to 14 times placebo rate - - Every-two-week dose data reinforces pegozafermin's pot

      3/22/23 7:00:00 AM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

      - Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW dose; p<0.001) in triglycerides (TG) from baseline; results were consistent in patients on or not on background therapy - - Observed significant and potent reductions in atherogenic lipids (non-HDL-C and apo B), liver fat, and improvements in liver enzymes and glycemic control markers - - ENTRIGUE results support 89bio's transition to a late-stage development company; Phase 3 expected to initiate in first half of 2023 - - Conference call and webcast today at 1:30 p.m. PST/4:30 p.m. EST - SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) -- 89bio, In

      6/28/22 4:01:00 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update

      - Interim data from NL-201 Phase 1 trial for patients with relapsed and refractory solid tumors anticipated in the second half of 2022 – - $142.5 million in cash and cash equivalents expected to provide runway into the second half of 2023 – - Appointment of Rohan Palekar to Board of Directors – - Company to host conference call today, March 1, 2022 at 1:30 p.m. PT / 4:30 p.m. ET – SEATTLE, March 01, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the year ended December 31, 2021.

      3/1/22 4:03:00 PM ET
      $ETNB
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care